Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. It typically develops in early childhood and can persist into adulthood. The standard first-line treatment for AD is topical immunotherapy, which has proven broadly effective in managing symptoms. In topical-refractory patients, symptoms are commonly managed by systemic immunomodulators, which can have serious side effects when administered over the long term. The launches of Pfizer’s Eucrisa (crisaborole), Sanofi / Regeneron’s Dupixent (dupilumab), LEO Pharma’s Adbry (tralokinumab), two oral JAK inhibitors (AbbVie’s Rinvoq [upadacitinib] and Pfizer’s Cibinqo [abrocitinib]), and one topical JAK inhibitor (Incyte’s Opzelura [ruxolitinib]) have greatly expanded treatment options for pediatric patients with AD across the severity spectrum. This claims data analysis explores the usage patterns of these newer therapies relative to historical mainstays of treatment and provides valuable insight into evolving drug treatment trends in pediatric AD.
Questions answered
Markets covered: United States
Key companies: LEO Pharma, Pfizer, Sanofi / Regeneron, Incyte, AbbVie
Key drugs: Adbry, Cibinqo, Dupixent, Eucrisa, Opzelura, Rinvoq
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses